NT1-O14B/PBA-Q76-O16B = 3:7 w/w was mixed with (-27)GFP-Cre at protein:lipids = 1:4 w/w for 15 min. Four 50-microgram IV injections on days 0, 5, 10 and 15 produced tdTomato-positive cells in cerebral cortex, hippocampus and cerebellum; pure-lipid controls did not.
Ai14 mice, n=3 per group; brain collected day 20 · Main Fig.4 and Methods: In vivo delivery of GFP-Cre proteinsales@dcchemicals.com
NT1-O14B
Formulation & Performance
Literature-reported formulation composition
| Component | Reported mass ratio (w/w) | Role |
|---|---|---|
| NT1-O14B | 3 | Ionizable lipid |
| 306-O12B-3 | 7 | Additional lipid components |
| DSPE-PEG2000 (1 part per 24 parts mixed synthetic lipids) | 1:24 | PEG lipid |
| Reported ratio sum | Not reported | Original ratio retained |
Formulation calculator unavailable. The source reports nested mass ratios and an average-mass PEG material, not a complete molar composition. No molar component-weight calculation is applied. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Literature-reported performance for the cited formulation
Literature-reportedApproximately 50%NT1-O14B/306-O12B-3 = 3:7 w/w; Tau-ASO:total lipids = 1:15 w/w; 1 mg/kg IV ×5 · Brain collected on day 20 · Pure NT1-O14B, pure 306-O12B-3, saline and scrambled ASO controls did not show the same reductionMain Results and Fig.3C
Literature-reportedApproximately 30%NT1-O14B/306-O12B-3 = 3:7 w/w; same Tau-ASO regimen · Day 20 · Saline and scrambled Tau-ASOMain Discussion and Fig.3D
Estimated from figureAbout 175 nm, PDI about 0.18 and zeta potential about -16 mVNT1-O14B/306-O12B-3 = 3:7 w/w with ASOApproximate readings from plotted bars; the supplement does not print a numeric table.Supplementary Fig.S10A-B, pp.14-15
Additional reported findings
Supplementary Fig.S10 shows approximately 142 nm diameter, PDI approximately 0.24 and zeta potential approximately +15 mV for the loaded 3:7 NT1-O14B/PBA-Q76-O16B formulation.
Approximate values read from plotted bars; not a numeric table · Supplementary Fig.S10A-B, pp.14-15Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetMa F, Yang L, Sun Z, et al. Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection. Science Advances. 2020;6:eabb4429. DOI: 10.1126/sciadv.abb4429
Tau-ASO and Cre-protein results are shown as two distinct NT1-O14B mixed formulations. Pure NT1-O14B controls did not reproduce the reported intracellular effects.
Tau-ASO and Cre-protein results are shown as two distinct NT1-O14B mixed formulations. Pure NT1-O14B controls did not reproduce the reported intracellular effects.